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Summary A method to determine the binding ofepidermal growth factor (EGF) to the particulate fraction of
the cell has been established and evaluated using rat liver, human placenta, and tumours of human breast and
brain. Little EGF receptor (EGFR) activity was detected in normal or benign tumour tissues except for
meningioma (positive in 95% samples), but EGFR were present in 43% of 131 breast tumours and 75% of 55
primary cerebral tumours. Despite the strong inverse correlation between EGFR activity and oestrogen
receptors in breast tumours and a tendency for high levels of EGFR activity to be associated with glioblas-
toma multiforme, analysis showed that EGFR was of little prognostic significance in patients with tumours of
either breast or brain.
Recent advances in our understanding of the ways in which
alterations in DNA can lead to cancer have suggested two
major mechanisms (Ponder, 1988) namely (1) the overactivity
of certain genes ('oncogenes') involved in transducing the
signals for growth and (2) the loss of other genes ('tumour
suppressor' or 'anti-oncogenes') which regulate differentiation
and limit growth. One putative component of the former
mechanism is epidermal growth factor (EGF), a small (Mr
6,045) peptide which acts through a larger, cell-surface recep-
tor protein (EGFR, Mr 180,000). This receptor protein is
structurally related to the product of a known oncogene
(v-erb B,). Potentially, overexpression of either the growth
factor or its receptor could contribute to the process of
carcinogenesis. Reports in the literature have suggested that
over-expression of the receptor protein may occur in several
types of tumour (Neal et al., 1985; Hwang et al., 1986;
Cowley et al., 1986), including those of the brain (Lieberman
et al., 1985) and breast (Sainsbury et al., 1985). Whether the
growth factor or its receptor are involved in carcinogenesis in
man is as yet unclear.
In established breast tumours, expression of the EGF
receptor protein has been reported to be an index of poor
prognosis (Sainsbury et al., 1985; 1987), likelihood of lymph
node involvement (Battaglia et al., 1988) and lack of re-
sponse to endocrine therapy (Nicholson et al., 1989). The
expression of EGF receptors shows a strong inverse correla-
tion with that of oestrogen receptors (Sainsbury et al., 1985;
Perez et al., 1984; Delarue et al., 1988) and thus to some
extent, measurements of EGFR may provide the same infor-
mation as that derived from ER measurements.
In malignant gliomata, over-expression of the EGFR pro-
tein appears to be associated with gene amplification (Wong
et al., 1987). In culture, the growth of glial tumour cells can
be stimulated by EGF (Frappaz et al., 1988) and antibodies
against the EGFR can inhibit such stimulation (Werner et
al., 1988). Clinically, an antibody against the EGFR, labelled
with 'l3I, has been reported to have induced significant
regression of a glioma in a young man (Epenetos et al.,
1985), though the specificity of this effect is uncertain.
In view of the above considerations, we set out (1) to
measure the levels of EGFR activity in series of intracranial
and breast tumours and (2) to relate these findings to the
patient's outcome. In view of the established significance of
the oestrogen receptor (Knight et al., 1977; Adami et al.,
1985), we have also examined the results for this protein in
the breast tumours.
Materials and methods
Radiochemicals
Initially, 125I iodide, carrier-free (Cat. No IMS 30) was pur-
chased from Amersham International, Little Chalfont, Bucks.
and used to prepare '25I EGF. A total of 19 iodinations were
carried out using either iodogen (Fraker & Speck, 1978;
n = 16) or lactoperoxidase (Thorell & Johnson, 1971; n = 3).
The radioactive EGF thus prepared was stored in aliquots at
-40°C until required, for up to 1 month. The specific radio-
activity of the preparations used ranged from 76 to 196 gsCi
Ag' i.e. 2.8-7.3 MBq ig-'. Because of the unpredictability
of these iodinations in our hands, we changed over to pur-
chasing the radioligand.
1251 EGF (152-177gLCitLg- i.e. 5.6-6.6MBqftgg', Cat.
No NEX-160) was purchased from Du Pont (UK) Ltd,
Wedgewood Way, Stevenage, Herts. and used without repuri-
fication.
[2,4,6,7-3H]oestradiol-17P (85-110 Ci mmol-' or 3.1-4.1
TBlq mmol, Cat. No TRK 322) was purchased from Amer-
sham International and repurified on Sephadex LH-20 (Mik-
hail et al., 1971) at 3-weekly intervals.
Non-radioactive chemicals
Epidermal growth factor was obtained in three forms: (1)
mouse EGF, tissue culture grade (Cat. No E7755) and (2)
mouse EGF, receptor grade (Cat. No E6135) were both
obtained from the Sigma Chemical Co. Poole, Dorset, UK,
while (3) human EGF (Mr 6216) was a recombinant prepara-
tion given by Dr H. Gregory of ICI Ltd, Pharmaceuticals
Division, Macclesfield, Cheshire.
Iodogen (1,3,4,6 tetrachloro-3ax-6m-diphenyl glycouril) was
obtained from the Sigma Chemical Company.
Sephadex G-25 and LH-20 were obtained from Pharmacia
Ltd, Milton Keynes, Bucks.
All other chemicals were obtained from either the Sigma
Chemical Company or from BDH Ltd, Poole, Dorset.
Patients
(a) With intracranial tumours Tissue specimens of intra-
cranial neoplasms were obtained from 88 patients undergoing
surgery in the Department of Clinical Neurology, Western
General Hospital, Edinburgh. A total of 96 specimens were
obtained. The patients ranged from 2 to 84 years of age and
the specimens were classified according to Burger et al. (1985)
and Russell and Rubenstein (1989).
In 11 patients, specimens of normal, peri-tumoral brain
were available from the material excised at operation (eight
specimens from patients where tumour was also available
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and three where no other tissue was available). The remain-
ing 85 abnormal tissues included 51 gliomata which were
further divided into 47 commoner types and four rarer types.
Follow-up time for all these patients ranged from 1-105
months (median 9 months). Follow-up was analysed only for
the 51 patients with tumours of the commoner types, i.e. 47
commoner gliomata and four primitive neuro-ectodermal
tumours (PNETs), since the natural history of meningiomas
and schwannomas necessitates long-term follow-up to docu-
ment recurrence (Simpson, 1957). In these patients, surgery
was by craniotomy and debulking in all patients except one
with a PNET who had craniotomy and biopsy only.
(b) With tumours of the breast For 151 female patients
undergoing surgery for a lesion of the breast between 16-09-
86 and 24-06-88, a specimen was submitted for oestrogen
receptor analysis and sufficient material was present for the
additional assay of EGFR. Of these patients, nine had
benign lesions, one had a melanoma, five had specimens
containing an inadequate sample (< 10%) of tumour (Steele
et al., 1987), two had squamous carcinoma, one had a malig-
nant histiocytoma, one bilateral breast carcinoma and for
one patient, no notes were available.
For the remaining 131 cases with a single breast cancer
and adequate tumour specimen, tumour stage ranged from
T1s to T4 and age from 27 to 87 years. One case had been
treated initially in 1959 and was also omitted from analysis.
Some data were missing in a further four cases and six had
metastases (MI) at presentation. The net result was that for
the study of survival, 126 cases were available and for that of
disease-free interval 123 (life-table analysis) or 120 (univari-
ate and multivariate analysis).
Follow-up time for this mixed group of patients was rela-
tively short (median 20, range 2-73 months).
Determination ofEGF receptor activity
The method used is based on that of Sainsbury et al. (1985).
After examination of the steps involved in the assay separ-
ately, the following procedure was adopted routinely.
(1) Preparation of 'membranes' In general, 200 to 600 mg
of fat-free tissue were chopped and homogenised in 2 ml
tris-monothioglycerol-glycerol buffer (tris 10 mM, 0.25 M suc-
rose, 1 mM EDTA, pH 8.0, plus 1% v/v monothioglycerol
and 10% v/v glycerol) using one burst of 20 s, 1 min pause
for cooling and a second burst of 15 s, maximum speed in a
Silverson metal homogeniser. The homogenate was kept on
ice and filtered through a coarse metal sieve to remove
lumps. The homogeniser and sieve were washed in 2 x 1.0 ml
of buffer and the homogenate plus washings was remixed and
centrifuged for 30 min at 105,000 g and 4°C in a Beckman
TLI00 ultracentrifuge.
The resulting pellet ('membranes' = total particulate frac-
tion) was resuspended in tris-saline buffer (1O mM, 0.15 M
NaCl, pH 7.4) to give a final concentration of 200-266 mg
tissue ml-' for breast tissues (in seven tissues only 140-190
mgml1' was possible) or 50-250mg tissueml1' for brain
tissues. The resuspended 'membranes' were rehomogenised
gently by hand in a glass-glass homogeniser to ensure com-
plete resuspension.
(2) Incubation One hundred microlitre portions of 'mem-
branes' (i.e. generally = 20-26 mg tissue per tube for breast
tissues and = 5-25 mg tissue per tube for brain tissues) were
distributed, where possible, into each of 15 tubes, containing
200,l non-radioactive EGF solution (to yield final concen-
trations of 0.024, 0.049, 0.098, 0.195, 0.39, 0.78, 1.56, 3.125,
6.25, 12.5, 25.0, 50.0, 100.0 or 300 nMolar), and 100pi of 1251
EGF (approximately 10,000 c.p.m., to yield a final concentra-
tion of approximately 0.02 nMolar), on ice. The contents of
each tube (total volume 400 AI) were mixed and the tubes
were incubated for 90 min at 26°C.
(3) Termination All tubes were placed on ice and to each
was added 0.5 ml of immunoglobulin G solution (0.5% w/v)
and 1.0ml of polyethylene glycol solution (25% v/v) with
mixing between the additions. The tubes were remixed and
centrifuged immediately for 15 min at 2,100g in the swing-
out-rotor of a precooled, MSE Mistral 6L centrifuge. After
centrifugation, the supernatant (free) fraction was aspirated
from each tube and the remaining pellet (bound) was count-
ed for 2 x 10 min in a Packard Multi-Prias Gamma Counter
at approximately 70% efficiency. Three tubes containing only
1251I EGF ('radioligand') were also counted to yield the start-
ing c.p.m./tube.
(4) Calculation of receptor site concentration After correc-
tion of the counts bound in each tube by subtraction of the
value for non-specific binding (300 nMolar tube), the data
were subjected to Scatchard (1949) analysis. Non-specific
binding averaged 8.9% of the total radioligand added
(n = 30). EGFR activity was designated as positive when
> 150 c.p.m. were displaced over at least four of 15 tubes by
non-radioactive EGF in the initial (high affinity) part of the
curve. Where no displacement was evident, the tissue was
designated EGFR - negative. Cases showing only a small
displacement and where a Scatchard plot was not possible
were designated as 'EGFR equivocal'.
For quantitative purposes, routinely curves were drawn by
hand and extrapolated to the horizontal axis to yield an
estimate of the total binding sites (high + low affinity sites)
present. Subsequently we examined many of the plots by the
computer-analysis method of Hetherington (Sainsbury et al.,
1985; Nicholson et al., 1988) to assign, fit and calculate both
the slopes and x-axis intercepts where two components were
present. Retrospective comparison of the extrapolation
method with the computer - analysis method showed very
little error (total sites from extrapolation = 98.1% value from
computer analysis, n = 17 assays on rat liver membranes).
'EGFR - equivocal' tissues were arbitrarily assigned a total
receptor site concentration of 5 fmolmg'- membrane pro-
tein, though in some EGFR - positive tissues, values as low
as 1 fmol mg-' membrane protein were derived by calcula-
tion.
A sample of rat liver membranes was processed, as a
quality control, with each batch of samples. These memb-
ranes, prepared in bulk and stored in aliquots at -40°C, lost
activity gradually on storage (approx 47% over 10 months)
but were nevertheless useful. The inter-assay coefficient of
variation for total sites in rat liver (measured over only 1
month) was 21% (n=6), 38% (n=7), 23% (n=6), and
30% (n = 6) for four different months, the mean loss of
activity being 4.7% per month on storage.
In preliminary experiments, we investigated (a) the
influence of the subcellular fraction chosen on binding, (b)
three different methods for separating free and bound pep-
tide, (c) the influence of time and temperature on binding
and (d) the specificity of the binding observed.
Determination ofoestrogen receptor activity
Oestrogen receptor activity was determined by the method of
Hawkins et al. (1975, modified 1981) on the supernatant
remaining from EGFR assay or prepared by homogenisation
of a separate, adjacent portion of tissue. The data were
analysed according to Scatchard (1949) using a BBC micro-
computer to yield the dissociation constant of binding (Kd
nmols I') and receptor site concentration (fmols mg' solu-
ble protein).,
Quality controls, consisting of pools of minced human
myometrium were processed with every assay and the inter-
assay coefficients of variation were 17.0% (n = 48) at high
levels (111 fmol mg-' protein) and 25.5% (n = 144) at lower
levels (48 fmol mg-' protein).
Determination ofprotein concentration
The protein contents of membrane preparations were deter-
mined after dissolution in 2 N sodium hydroxide solution andEGF RECEPTORS IN TUMOURS 555
neutralisation with 2 N HCI solution, by assay with Coo-
massie Blue reagent (Bradford, 1976) against a mixed protein
standard (Sigma, Cat. No 540-10). Tissue extracts ('cytosols')
were assayed directly. Five quality control samples were pro-
cessed with each assay and where the mean value deviated by
more than 10% from the expected, the assay was repeated.
Statistical evaluations
The inter-relationship between oestrogen and epidermal
growth factor receptor activities was examined by Kendall's
Rank Correlation Coefficient. The inter-relationship was also
examined by classifying breast tumours as EGFR-positive
(> 1 fmol mg-' protein) or EGFR-negative, and ER-positiv-
ity according to various cut-offs (5, 10, 15, 20, 30, 50 and
lOOfmolmg'I protein). Cohen's kappa was then calculated
(Cohen, 1960) to give a measure of the concordance between
EGFR-positivity and ER-negativity.
In order to examine the importance of each receptor activ-
ity in relation to prognosis (disease-free interval and survival
for breast tumours, survival for brain tumours), Cox's pro-
portional hazards regression model was applied in firstly,
univariate and secondly, multivariate analyses.
Specificity ofbinding
The specificity of binding of '25I EGF, tested in placenta, a
breast tumour and three brain tumours (Figure 2), showed
that there was no consistent increase in displacement of
binding with increasing concentration of competing protein/
peptide except with EGF among the compounds tested
(Figure 2). Culture grade EGF, displaced 76-81% of the
binding in placenta and a breast tumour and 29-44% in
three brain tumours. In the latter tissues, displacement by
both human and mouse EGF was in excess of 80% at
300 nM competitor for two of the three tumours examined,
but only attained 55% in the third.
Influence oftemperature
For three types of tissue, the time course of binding was
examined at various temperatures (Figure 3a, b and c). Using
a fixed, but non-saturating concentration of ligand (--0.15
nM), maximal specific binding was observed with rat liver
'membranes' after approximately 60 min at 26°C, lesser bind-
ing being observed at 4°C or 37'C (Figure 3a). In a breast
tumour (Figure 3b), maximal binding was observed after
approximately 40 min at either 26°C or 37°C and lower bind-
ing was observed at 4°C. For a brain tumour (Figure 3c), the
Results
Binding of125I EGF infour types oftissue
The binding of 125I EGF was determined in four kinds of
tissue: rat liver and human placenta (controls) and tumours
ofbreast and brain. Examples of the Scatchard plot obtained
for each type of tissue are shown in Figure 1. Inspection of
the plot revealed evidence for two binding compontents in
some tissues (rat liver always, others more variable) and one
in others. When the data were analysed by computer, the
Kds of the high and low affinity components were in the
ranges of 0.01-0.50 nM and 1.0-5.0 nM respectively (see
Figure 2), though the affinity in some brain tumours was
apparently rather different (see Discussion).
Since (1) initially we did not have the computer program
for separating the two components (2) there is no conclusive
evidence that lower affinity sites are of no significance, in the
results which follow, concentration of total receptor sites has
been calculated by extrapolation, unless stated otherwise.
Influence ofmode ofseparatingfree andboundligand
A comparison of three different methods for separating free
and bound ligand was carried out on rat liver membranes.
The methods were (A) simple centrifugation ofthe membranes
(Sainsbury et al., 1985) (B) filtration of the membranes
(based on Fitzpatrick et al., 1984) and (C) co-precipitation of
IgG with polyethylene glycol (based on Carpenter, 1985).
This showed that by method C, on average, slightly lower Kd
values (stronger binding) for both low and high affinity
components (ratios of Kdl by methods A: B: C = 3.49: 3.86:
1.00; Kd2= 1.82: 1.89: 1.00, means of four experiments by
computer analysis) and higher numbers of total receptor sites
(ratios A: B: C = 0.78: 0.87: 1.00) were observed than were
found by methods A or B. The Kd, and Kd2 values found by
this method, C, were also more consistent and this method
was selected for the routine procedure.
Influence ofsubcellularfraction analysed
When the total homogenate was separated by centrifugation
into subcellular fractions, binding activity was found in all
the particulate subcellular fractions (Table I). This was
especially evident in rat liver and brain tumours of the three
types of tissue examined. In view of this finding, for routine
purposes, we collected all the particulate fractions ('mem-
branes') of the cell for assay, by a single centrifugation at
108,000g.
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Figure 1 Binding of 125I EGF to four types of tissue: Scatchard
plots, analysed by computer for a, rat liver, b, placenta, c, breast
tumour and d, brain tumour.
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Figure 2 Specificity of binding of I251 EGF to three types of
tissue: a, placenta, b, breast tumour and c, brain tumour. Mem-
branes from 5-36mg tissue were exposed to 20,000 or 100,000
c.p.m. 1211 EGF (0.05-1.0 nM) in the presence or absence of
competing peptide (12.5-300nM) for 90min at 26°C.
time course of binding was different, binding being maximal
(26°C or 37°C) or nearly maximal (4C) after approximately
40 min and changing little thereafter. It was not possible to
perform all of these studies at the outset, and thus the
conditions of 90 min at 26°C, chosen for the routine assay,
represent a compromise.
Incidence and significance ofEGFR in breast tissue
Of nine samples of tissue designated 'normal/benign' on
histopathological examination, only one (11%) contained a
low level of EGFR activity.
Of the 131 samples from solitary breast cancers with ade-
quate tumour content, 56 (43%) had EGFR activity (> 1
fmol mg-' membrane protein) and 83 (63%) had ER activity
(>5 fmol mg-' soluble protein). There was an inverse cor-
Table I Distribution of EGFR amongst the subcellular fractions in
three types of tissue
Expt. Total EGFR in % activity in eachfraction
Tissue type no. allfractions (A) B C D E
Rat liver 1 18.1 40.7 33.2 26.1 0
2 5.47 64.0 24.6 11.4 0
3 16.2 52.8 35.9 11.3 0
4 2.26 31.4 15.5 53.1 0
5 7.35 24.9 42.8 30.5 1.8
6 6.91 31.7 22.3 46.0 0
Mean 40.9 29.1 29.7 0.3
Breast 1 16.8 5.0 5.1 89.9 0
tumours 2 2.96 3.0 33.8 63.2 0
3 2.97 33.6 12.5 53.9 0
4 0.59 32.5 30.8 36.7 0
Mean 18.5 20.6 60.9 0
Brain 1 94.6 29.0 33.5 31.7 5.8
tumours 2 40.6 35.4 27.7 36.9 0
3 1335.6 28.0 36.7 33.4 1.9
4 24.3 30.0 39.0 31.0 0
5 265.0 47.3 36.6 16.1 0
Mean 33.9 34.7 29.8 1.6
A = sum of total receptor sites derived by extrapolation of a
Scatchardplotforeachfraction,expressedasfmolsites mg-' wettissue;
B = 'nuclei/debris', 800g pellet; C ='low speed membranes', 800-
2,000 g pellet; D ='high speed membranes', 2,000-108,000g pellet;
E = 'cytosol', 108,000g supernatant.
relation between the presence of ER and that of EGFR
(Kendall's R= -0.35, P<0.001). By Cohen's Kappa test,
this inverse relationship was strongest (Cohen's Kappa
0.52-0.53) when a cut-off of 10-15 fmol mg' protein was
used to designate 'presence/absence' for the oestrogen recep-
tor.
At analysis, there had been 43 recurrences and 30 deaths.
When the relationship of the various clinical or biochemical
parameters to disease-free interval or survival was examined
by univariate analysis, only node status, tumour stage,
tumour size and oestrogen receptor concentration had a
significant influence (Table II). By multivariate analysis, only
node status and oestrogen receptor concentration influenced
prognosis (Table III). No clear relationship was shown
between EGFR activity and prognosis whilst higher levels of
ER activity (>100 fmolmg-' protein) were associated with
a longer disease-free interval (survival curves not shown).
Incidence andsignificance ofEGFR in brain tissue
EGFR activity was detectable in only one of 11 samples of
normal brain (9%), in 1/6 schwannomas (16%), 20/21 sam-
ples of meningioma (95%, median level 155 fmol mg-' pro-
tein), in 2/3 metastatic deposits from extracranial malignant
tumours and in 41/55 intracranial tumours (75%, median
level 44fmol mg ' protein). Within the gliomata, there were
marked differences between the levels of EGFR activity in
the different histopathological types of tumour (Table IV),
with very high levels being detected in some samples of
glioblastoma multiforme.
By univariate analysis, the patient's age, tumour type and
mode of primary treatment were significantly related to sur-
vival (Table V) whilst sex, type of specimen (10 or recurrence)
assayed and EGFR concentration had no influence. Patients
who were younger at presentation fared better than those
presenting later and survival related to tumour histological
type in the manner expected, i.e. increasing survival in the
order (1) glioblastoma multiforme, (2) anaplastic astro-
cytoma, (3) oligodendroglioma/mixed oligo-astrocytoma, (4)
PNET and (5) astrocytoma. In addition, patients treated by
surgery alone fared less well than those receiving combined
treatments.
Even though patients with high levels of EGFR activity
appeared to fare worse than those with lower levels (e.g.
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Figure 3 The time course of binding at three different tempera-
tures in three types of tissue: a, rat liver, b, breast tumour and c,
brain tumour.
Table II Relationship ofvarious factors to prognosis in patients with
breast cancer by univariate analysis
Significance level (P)
Factor DFI Survival
'Node status"' 0.0004 0.018
Tumour size 0.014 0.15
ER concentration 0.018 0.029
Tumour stage 0.079 0.048
Assay specimenb 0.24 0.79
EGFR concentration 0.27 0.45
Age 0.68 0.57
Menstrual status 0.70 0.73
Treatment 0.71 0.53
"'Nodestatus' = pathological nodestatuswhereknown,(n = 84)plus
"clinical node status' where former unknown (n = 42); bAssay specimen
refers to whether the assay was conducted on primary or secondary
tumour.
Table III Relationship ofvarious factors to prognosisin patients with
breast cancer by multivariate analysis
Significance level (P)
Factor DFI Survival
Factors included in the model:
'Node statusa 0.0004 0.018
ER concentration 0.0018 0.011
Factors rejectedfrom the model:
Tumour stage 0.12 0.61
Tumour size 0.12 0.86
Menstrual status 0.34 0.39
Treatment 0.42 0.67
EGFR concentration 0.60 0.99
Assay specimenb 0.66 0.22
Age 0.81 0.75
a"Node status' = pathological node statuswhere known (n = 84) plus
'clinical node status' where former unknown (n = 42); bAssay specimen
refers to whether the assay was conducted on primary or secondary
tumour.
Table IV Incidence and levels of EGFR activity in 96 intra-cranial
tissues
Median level ofEGFR
Noa EGFR+ activity
Tissue No (%) (fmolmg' protein)
Normal brain 11 1 (9%) 0
Schwannoma 6 1 (16%) 0
Meningioma 21 20 (95%) 155
Glioblastoma 28 26 (93%) 214
multiforme
Anaplastic 5 4 (80%) 28
astrocytoma
Astrocytomas 7 2 (29%) 0
Oligodendrogliomas 7 5 (71%) 50
/mixed oligo-
astrocytomas
PNET 4 2 (50%) 2
Rarerb 4 2 (50%) 22
malignancies
Metastatic 3 2 (66%) 5
deposits
PNET = primitive neuroectodermal tumour. 'Tissues showing any
evidence of specific binding (±) and clear positives (+) were taken as
EGFR+ for this calculation; bTwo cerebellar haemangioblastomas,
one sarcoma, one gliosarcoma.
Table V Relationship ofvarious factors to survival in 51 patientswith
primary cerebral neoplasms by univariate analysis
Factor Significance level (P)
Age <0.0001
Tumour type 0.0001
Treatment 0.029
Sex 0.064
EGFR concentration 0.14
Assay specimen 0.29
Assayspecimen refers towhetherassay wasconducted onprimary or
secondary tumour.
Figure 4a), this effect was due to the association between
high levels of EGFR activity and a particualr tumour type
(glioblastoma multiforme) and the apparent influence of
EGFR level on survival disappeared when only a single
tumour type was considered (Figure 4b). By multivariate
analysis, again only age, tumour type and mode of treatment
influenced survival (Table VI), other factors being rejected
from the model.
Discussion
In this paper, we have established and examined an assay for
EGFR. For this assay, we have preferred to separate free558 R.A. HAWKINS et al.
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TableVI Relationshipofvarious factors to survival in 51 patientswith
primary cerebral neoplasms: multivariate analysis
Factor Probability value (P)
Factors included in the model
Treatment 0.0019
Tumour type 0.0026
Age 0.021
Factors rejectedfrom the model
Sex 0.22
Assay specimen 0.61
EGFR concentration 0.65
Assay specimen refers to whether assay was conducted on primary or
secondary tumour.
and bound hormone by co-precipitation, and to measure the
total receptor site concentration present in the total parti-
culate fraction of the cell. Others have used a variety of
ligand-binding methods (e.g. Nicholson et al., 1988), or an
autophosphorylation method (Lieberman et al., 1985), and
slightly different subcellular fractions (e.g. Sainsbury et al.,
1985; Fitzpatrick et al., 1984; Perez et al., 1984). Most tis-
sues, in our experience, demonstrated both high and low
affinity binding sites; since the significance of these two types
of site is unclear, though it might relate to the degree of
aggregation of the EGFR monomers (Schlessinger, 1988) and
since it was technically simpler, we preferred to measure total
sites. Equally, since EGFR binding activity was found in all
the subfractions of the cell, for ease of preparation and for
maximal sensitivity, we assayed the total receptor sites pre-
sent in the cell. Of the compounds tested, only EGF of
human or mouse origin significantly displaced 125I EGF from
binding in three types of tissue examined; on a molar basis,
we did not observe any consistent difference in relative bin-
ding affinity between EGFs from the two different sources.
Despite the above examination of the assay method, while
the assay of samples of placenta and rat liver was straight-
forward, some difficulties were encountered with samples
from tumours of brain or breast. For the former, binding
was occasionally very high or gave anomalous Scatchard
plots with apparently low affinity binding (Kd 10-60 nM)
even when reassayed at lower dilutions of the membranes.
This coupled with the different time course of binding sug-
gested that the EGFR in brain tumours may differ from
those in other tissues, or that the apparent differences were
due to technical factors (tissue damage at/after operation, or
assay of samples containing too many receptors for satura-
tion). For the breast tumours, in general, the binding of EGF
was very low and thus accurate separation of the Scatchard
plot into two components would have been difficult. These
analyses of EGFR activity, therefore, are probably quanti-
tatively approximate, but qualitatively accurate.
EGF receptor activity was detected in 11% (1/9) samples
of benign breast tissue and 9% (1/11) samples of normal
brain and in agreement with the immunocytochemical find-
ings of Horsfall et al. (1989), in virtually all the meningiomas
(20/21 = 95%) examined. The significance of the latter obser-
vation is as yet unclear, though like breast cancers, with
which they show an association (Rubinstein & Schein, 1989),
meningiomas also may contain steroid receptors (Whittle et
al., 1987; Horsfall et al., 1989). Maligant tumours of the
breast contained some binding activity in 43% of the 131
tumours examined, whilst those of the brain contained
activity in 75% of the 55 intracranial cases.
In the case of breast cancer, our study population was a
mixture of patients at all stages in the course of the disease,
treated at nine different hospitals. They represent a group of
patients with larger tumours and a poor prognosis; there
were 43 recurrences and 30 deaths in the relatively short
follow-up period, and only 63% of the tumours contained
detectable ER activity (c.f.> 75% in unselected patients in
our experience - Hawkins et al., 1987). By both univariate
and multivariate analyses, in contrast to the findings of the
Newcastle group (Sainsbury et al., 1985, 1987; Nicholson et
al., 1989), EGFR measurements were of no prognostic value
and only node status and ER measurements related signi-
ficantly to disease-free interval or survival (Table III). How-
ever, it is to be noted that EGFR and ER show a strong
inverse relationship, and thus to some extent, they provide
the same information. The reasons for the difference between
our findings and the previous reports are not clear but they
could relate to (1) insufficient sensitivity in our EGFR assay,
particularly where only small samples of tumour were
available, (2) our study of total EGFR sites (c.f. high affinity
sites by the Newcastle workers), though this seems unlikely
since EGFR + tissues generally contained high affinity sites
and (3) the fact that the tumours studied constitute a selected
group which is probably not representative of the spectrum
of breast cancers. Other workers have also examined the
prognostic value of EGFR measurements but the results haveEGF RECEPTORS IN TUMOURS 559
been contradictory. Grimaux et al. (1989), examining a small
subgroup of 55 patients, found that EGFR status was an
important prognostic factor by both univariate and multi-
variate analyses at 40 months of follow-up. By contrast,
Foekens et al. (1989), in a larger group of 214 patients,
found that, as in the present study, steroid receptor status,
but not EGFR status, was of prognostic value.
For brain tumours, to our knowledge, the prognostic value
of EGFR measurements has not been examined previously.
In the present series, although there was a tendancy for
tumours of the most aggressive histological type (glioblas-
toma multiforme) to produce high levels of EGFR, multi-
variate analysis revealed that only age, histopathological
tumour type and type of treatment related to survival.
Our findings ofhigh levels ofexpression ofEGFR by some
gliomata are in agreement with those of others (Liebermann
et al., 1985; Wong et al., 1987; Helseth et al., 1988). This
overexpression has been found frequently to be associated
with gene amplification (Liebermann et al., 1985; Helseth et
al., 1988) and the process appeared to confer a growth
advantage upon suspensions of single cells from human glio-
mata, grown in agar (Helseth et al., 1988). Glioma cell lines
in culture are, in some cases, sensitive to EGF and can be
inhibited by an antibody against the EGFR (Werner et al.,
1988). In vivo, four of seven patients with recurrent gliomata
localised by immunoscintigraphy using '25I-labelled anti-
bodies against EGFR and treated with "3'N-labelled antibody
have shown clinical improvement (Kalofonos et al., 1989).
Despite these observations, Collins (Collins, P. Sweden -
personal communication to I.R.W.), in line with our own
findings on EGFR expression, found no correlation between
EGFR gene amplification and survival.
In summary, we conclude that the EGFR protein tends to
be expressed in malignant tumours of poorer prognosis in
both breast and brain. However, the extent of this expression
in variable and not sufficiently consistent, by our mode of
analysis, to be of prognostic significance. Re-examination of
this question with a more sophisticated and sensitive assay or
in a wider spectrum of breast cancers could alter that con-
clusion.
We wish to thank particularly, members ofthe Department ofSurgery
in Newcastle, Mr Richard Sainsbury, MrsPauline Chambers and Clive
Hetherington (Biochemistry) for help and discussion of their tech-
niques. Dr Tony Bramley, MRC Centre for Reproductive Biology,
Edinburgh also helped by discussion and provision ofthe details ofhis
co-precipitation technique.
We thank Dr Jeanne Bell, Department ofNeuropathology, Univer-
sity of Edinburgh for classifying the intra-cranial tumours and other
members ofthe Department ofPathology forselectingthebreastcancer
tissue for assay and for confirmation/otherwise of the presence of
tumour. Dr Ian Nimmo, Department of Biochemistry, University of
Edinburgh also helped with advice and discussion of the computer
analysis of Scatchard plots.
Dr H. Gregory, ICI Ltd, kindly provided us with the sample of
recombinant human EGF and Dr D. Pepper, Scottish National Blood
Transfusion Service Headquarters Laboratory, 2 Forrest Road, Edin-
burgh gave us a preparation enriched in PDGF.
We are grateful to Dr Helen J. Stewart, Director of the Scottish
Cancer Trials Office (MRC), Professor D.C. Carter and Professor Sir
Patrick Forrest for advice and encouragement. Ms Elizabeth Hunter
and Ji Xian Wang, Medical Statistics Unit, kindly helped with the
analysis of the data.
Thework was supported, in part, by funding from the Melville Trust
to Mr Whittle and Dr Hawkins.
Oestrogen receptor assays were performed by Ann L. Tesdale and
David Carson with the support of the Lothian Health Board.
References
ADAMI, H.O.,GRAFFMAN, S.,LINDGREN, A. &SALLSTROM, J. (1985).
Prognosticimplication ofestrogen receptorcontent inbreastcancer.
Breast Cancer Res. Treatment, 5, 293.
BATTAGLIA, F., SCAMBIA, G., ROSSI, S. & 8 others (1988). Epidermal
growth factor receptor in human breast cancer: correlation with
steroid hormone receptors and axillary lymph node involvement.
Eur. J. Cancer Clin. Oncol., 24, 1685.
BRADFORD, M.M. (1976). A rapid and sensitive method for the
quantitation ofmicrogram quantities ofprotein utilizing the prin-
ciple of protein-dye binding. Analyt. Biochem., 72, 248.
BURGER, P.C., VOGEL, F.S., GREEN, S.B. & STRIKE, T.A. (1985).
Glioblastoma multiforme and anaplasticastrocytoma: pathological
criteria and prognostic implications. Cancer, 56, 1106.
CARPENTER, G. (1985). Binding assays for epidermal growth factor
p101-i 10. In Methods in Enzymology, 109, Academic Press.
COHEN, J. (1960). A coefficient of agreement for nominal scales.
Educational and Pyschological Measurement, 20, 37.
COWLEY, G.P., SMITH, J.A. & GUSTERSON, B.A. (1986). Increased
EGF receptors on human squamous carcinoma cell lines. Br. J.
Cancer, 53, 223.
DELARUE, J.C., FRIEDMAN, S., MOURIESSE, H., MAY-LEVIN, F.,
SANCHO-GARNIER, H. & CONTESSO, G. (1988). Epidermal growth
factor receptor in human breast cancers: correlation with estrogren
and progesterone receptors. Breast Cancer Res. Treatment, 11, 173.
EPENETOS, A.A., COURTENAY-LUCK, N., PICKERING, D. & 4 others
(1985). Antibody-guided irradiation of brain glioma by arterial
infusion of radioactive monoclonal antibody against epidermal
growth factor receptorand blood group A antigen. Br. Med. J., 290,
1463.
FITZPATRICK, S., BRIGHTWELL, J.,WITTLIFF, J.L., BARROWS, G.H. &
SCHULTZ, G.S. (1984). Epidermal growth factor binding by breast
tumourbiopsiesandrelationship toestrogenandprogestinreceptor.
Cancer Res., 44, 3448.
FOEKENS, J.A., PORTENGEN, H., VAN PUTTEN, W.L.J. & 4 others
(1989). Prognostic value ofreceptors forinsulin-like growthfactorI,
Somatostatin and epidermal growth factor in human breast cancer.
Cancer Res., 49, 7002.
FRAKER, P.J. & SPECK, J.C. (1978). Protein and cell membrane
iodination with a sparingly soluble chloramide 1,3,4,6 tetrachloro
3a6adiphenylglyrouril. Biochem. Biophys. Res. Commun., 80, 849.
FRAPPAZ, D., SINGLETARY, S.E., SPITAZER, G. & YUNG, A. (1988).
Enhancement ofgrowth ofprimarymetastaticfreshhumantumours
of the nervous system by epidermal growth factor in serum-free
short term culture. Neurosurgery, 23, 355.
GRIMAUX, M., ROMAINS, S., REMVIKOS, Y., MARTIN, P.M. & MAG-
DELENAT, H. (1989). Prognosticvalueofepidermalgrowthfactorin
node-positive breast cancer. Breast Cancer Res. Treatment, 4, 77.
HAWKINS, R.A., BLACK, R., STEELE, R.J.C., DIXON,J.M.J. &FORREST,
A.P.M. (1981). Oestrogen receptor concentration in primary breast
cancer and axillary node metastases. Breast Cancer Res. Treatment,
1, 245.
HAWKINS, R.A., HILL,A.&FREEDMAN, B.(1975). Asimplemethodfor
the determination of oestrogen receptor concentrations in breast
tumours and other tissues. Clinica Chimica Acta, 64, 203.
HAWKINS, R.A., WHITE, G., BUNDRED, N.J. & 4 others (1987).
Prognostic significance of oestrogen and progestogen receptor
activities in breast cancer. Br. J. Surgery, 74, 1009.
HELSETH, E., UNSGAARD, G., DALEN, A. & 4 others (1988). Ampli-
fication of the epidermal growth factor receptor gene in biopsy
specimens from humanintracranial tumours. Br. J. Neurosurgery, 2,
217.
HORSFALL, D.J., GOLDSMITH, K.G., RICCIARDELLI, C., SKINNER,
J.M.,TILLEY,W.D.&MARSHALL,V.R.(1989). Steroidhormoneand
epidermal growth factor receptors in meningiomas. Aust. NZSurg.,
59, 881.
HWANG, D.L.,TAY, Y.C., LIN, S.S.&LEV-RAN,A. (1986). Expression of
epidermal growth factor receptors in human lung tumours. Cancer,
58, 2260.
KALOFONOS, H., PAWLIKOWSKA, T.R.B., SNOOK, D.E. & 4 others
(1989). Radiolabelled monoclonal antibodies for localisation and
therapy of brain gliomas. Br. J. Cancer, 59, 318.
KNIGHT, W.A., LIVINGSTON, R.B., GREGORY, E.J. & MCGUIRE, W.L.
(1977). Oestrogen receptor as an independent prognostic factor for
early recurrence in breast cancer. Cancer Res., 37, 4669.
NEAL, D.E., MARSH, C., BENNETT, M.K. & 4 others (1985). Epidermal
growth factor receptors in human lung tumours. Cancer, 58, 2260.
NICHOLSON, S., SAINSBURY, J.R.C., HALCROW, P., CHAMBERS, P.,
FARNDON, J.R. & HARRIS, A.L. (1989). Expression of epidermal
growth factor receptors associated with lack of response to endo-
crine therapy in recurrent breast cancer. Lancet, i, 182.560 R.A. HAWKINS et al.
NICHOLSON, S., SAINSBURY, J.R.C., NEEDHAM, G.K., CHAMBERS, P.,
FARNDON, J.R. & HARRIS, A.L. (1988). Quantitative assays of
epidermal growth factor receptor in human breast cancer: cut-off
points ofclinical relevance. Int. J. Cancer, 42, 36.
PEREZ, R., PASCUAL, M., MACIAS, A. & LAGE, A. (1984). Epidermal
growth factor receptors in human breast cancer. Breast Cancer Res.
Treatment, 4, 189.
PONDER, B. (1988). Gene losses in human tumours. Nature, 335, 400.
RUBENSTEIN, A.B. &SCHEIN, M. (1989). The association ofcarcinoma
of the breast with meningioma. Surgery Gynecology & Obstetrics,
169, 334.
RUSSELL, D.S. &RUBENSTEIN, L.J. (1989). PathologyofTumoursofthe
Nervous System. E. Arnold: London, 5th edition.
SAINSBURY, J.R.C., FARNDON, J.R., NEEDHAM, G.K., MALCOM, A.J.
&HARRIS, A.L. (1987). Epidermal growth factor receptorstatusas a
predictor of early recurrence of and death from breast cancer:
correlation with steroid hormone receptors andaxillarylymph node
involvement. Eur. J. Cancer Clin. Oncol., 24, 1685.
SAINSBURY, J.R.C., FARNDON, J.R., SHERBET, G.V. & HARRIS, A.L.
(1985). Epidermal growth factor receptors and oestrogen receptors
in human breast cancer. Lancet, i, 364.
SCATCHARD, G. (1949). The attraction ofproteins for small molecules
and ions. Ann. NY Acad. Sci., 51, 660.
SCHLESSINGER, J. (1988). Signal transduction by allosteric receptor
oligomerisation. TIBS, x, 443.
SIMPSON, D.A. (1957). The recurrence of intracranial meningiomas
after surgical treatment. J. Neurol. Neurosurg. Psychiat., 20, 22.
STEELE, R.J.C., HAWKINS, R.A., ANDERSON, T.J. & FORREST, A.P.M.
(1987). The relevance of control histology in oestrogen receptor
estimation. Br. J. Cancer, 56, 517.
THORELL, J.I. & JOHNSON, B.G. (1971). Enzymatic iodination of
polypeptides with 1251 to high specific activity. Biochim. Biophys.
Acta, 251, 363.
WERNER, M.H., HUMPHREY, P.A., BIGNER, D.D. & BIGNER, S.H.
(1988). Growth effects of epidermal growth factor (EGF) and a
monoclonal antibody against the EGF receptor on four glioma cell
lines. Acta Neuropathol. (Berlin), 77, 196.
WHITTLE, I.R., HAWKINS, R.A. & MILLER, J.D. (1987). Sex hormone
receptors in intra-cranial tumours and normal brain. Eur. J. Surg.
Oncol., 13, 303.
WONG, A.J., BIGNER, S.H., BIGNER, D.D., KINZLER, K.W., HAMIL-
TON, S.R. & VOGELSTEIN, B. (1987). Increased expression of the
epidermal growth factor receptor gene in malignant gliomas is
invariably associated with gene amplification. Proc. Natl Acad. Sci.
USA, 84, 6899.